Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 2:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 12,478 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Treatment with Placebo Clear all
Completed Phase 4 Interventional

Escitalopram Treatment of Major Depression in Patients With Temporal Lobe Epilepsy

NCT00595699
View directory record Official record
Conditions
Major Depression, Temporal Lobe Epilepsy
Interventions
escitalopram, placebo
Drug
Lead sponsor
Conrad, Erich J., M.D.
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 17, 2011 · Synced Sep 11, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effectiveness of Antibiotic Treatment for Reducing Binge Eating and Improving Digestive Function in Bulimia Nervosa

NCT00304187
View directory record Official record
Conditions
Bulimia Nervosa, Eating Disorders
Interventions
Erythromycin, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2018 · Synced Sep 11, 2026, 2:03 AM EDT
Not listed Phase 2Phase 3 Interventional

The Effects of Exenatide After Gastric Restriction

NCT00872378
View directory record Official record
Conditions
Morbid Obesity
Interventions
Exenatide, Placebo
Drug
Lead sponsor
Advanced Specialty Care
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Bend, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 30, 2009 · Synced Sep 11, 2026, 2:03 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment Premature Ejaculation

NCT00556478
View directory record Official record
Conditions
Premature Ejaculation
Interventions
PSD502, contains a mixture of lidocaine and prilocaine, Placebo
Drug
Lead sponsor
Plethora Solutions Ltd
Industry
Eligibility
18 Years and older · Male only
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 25, 2016 · Synced Sep 11, 2026, 2:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Impact of Intravenous Bendavia™ on Endothelial Reactivity Dysfunction in Cigarette Smoking

NCT01518985
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Bendavia, Sterile saline (0.9%), Cigarette smoking
Drug · Other
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 18, 2012 · Synced Sep 11, 2026, 2:03 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

NCT04497844
View directory record Official record
Conditions
Metastatic Castration-sensitive Prostate Cancer
Interventions
Niraparib+ Abiraterone acetate fixed dose combination (FDC), Abiraterone acetate (AA), Prednisone, Placebo FDC, Placebo AA
Combination Product · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
696 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
53
States / cities
Homewood, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 11, 2026, 2:03 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)

NCT02623699
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Tofersen, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
20
States / cities
Phoenix, Arizona • La Jolla, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Sep 11, 2026, 2:03 AM EDT
Withdrawn Not applicable Interventional

Extended Treatment With Vancomycin for Clostridium Difficile Colitis

NCT00861887
View directory record Official record
Conditions
Clostridium Difficile Colitis
Interventions
Standard Vancomycin, Extended Vancomycin
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Sep 11, 2026, 2:03 AM EDT
Withdrawn Not applicable Interventional

Phenylephrine Dose and Mode of Administration for Spinal Anesthesia Induced Hypotension

NCT02101047
View directory record Official record
Conditions
Complications; Cesarean Section, Spinal Anesthetics Causing Adverse Effects in Therapeutic Use
Interventions
Phenylephrine
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Sep 11, 2026, 2:03 AM EDT
Enrolling by invitation Phase 2 Interventional

Neuroimaging of Escitalopram in Autism Spectrum Disorder

NCT06826326
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Escitalopram 10mg, Placebo
Drug
Lead sponsor
Kathryn Unruh
Other
Eligibility
12 Years to 17 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 11, 2026, 2:03 AM EDT
Completed Phase 4 Interventional Results available

Clinical Effects of Eptifibatide Administration in High Risk Patients Presenting With Non-ST Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Urgent Coronary Artery Bypass Graft Surgery in Short- and Long-Term Follow-up

NCT01863134
View directory record Official record
Conditions
Non ST Elevation Myocardial Infarction
Interventions
Eptifibatide, Placebo
Drug
Lead sponsor
Medical University of Silesia
Other
Eligibility
21 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Sep 11, 2026, 2:03 AM EDT
Recruiting Phase 2 Interventional

Semaglutide for Helping Opioid Recovery

NCT06639464
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Semaglutide, Placebo
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Sep 11, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Results available

Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban

NCT03326063
View directory record Official record
Conditions
Nasal Polyps, Asthma, Aspirin-Induced, Aspirin-exacerbated Respiratory Disease, Aspirin-Sensitive Asthma With Nasal Polyps
Interventions
Ifetroban, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Sep 11, 2026, 2:03 AM EDT
Completed Phase 3 Interventional Results available

"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"

NCT02348606
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
JZP-110, Placebo oral tablet
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
476 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
45
States / cities
Glendale, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Sep 11, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Results available

QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer

NCT00626106
View directory record Official record
Conditions
Breast Cancer, Breast Tumors, Metastatic Cancer
Interventions
AMG 479, Placebo
Drug
Lead sponsor
NantCell, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
25
States / cities
Chandler, Arizona • Anaheim, California • Beverly Hills, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 11, 2026, 2:03 AM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected Controllers

NCT03060447
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Vesatolimod, Placebo, ART
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Ft. Pierce, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Sep 11, 2026, 2:03 AM EDT
Terminated Phase 2 Interventional Results available

Benzodiazepines for the Reduction of Distress and Pain During and After Emergency Department Care

NCT03756038
View directory record Official record
Conditions
Acute Pain
Interventions
Placebos, Lorazepam
Drug
Lead sponsor
Maria Pacella
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 8, 2020 · Synced Sep 11, 2026, 2:03 AM EDT
Withdrawn Phase 2 Interventional

Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial

NCT07349771
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Axatilimab, Biospecimen Collection, Bone Marrow Aspiration, Computed Tomography, Cyclophosphamide, Magnetic Resonance Imaging, Mycophenolate Mofetil, Placebo Administration, Positron Emission Tomography, Skin Biopsy, Tacrolimus, X-Ray Imaging
Procedure · Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 11, 2026, 2:03 AM EDT
Completed Phase 3 Interventional

A Double-Blind Randomized Placebo Controlled Study of Quetiapine for the Treatment of Depression in Adolescents With Bipolar Disorder

NCT00232414
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Quetiapine
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
12 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 9, 2013 · Synced Sep 11, 2026, 2:03 AM EDT
Active, not recruiting Phase 3 Interventional

Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency:

NCT02616484
View directory record Official record
Conditions
Pyruvate Dehydrogenase Complex Deficiency
Interventions
Dichloroacetate (DCA), Placebo, Genotype
Drug · Other · Genetic
Lead sponsor
Saol Therapeutics Inc
Industry
Eligibility
6 Months to 17 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
10
States / cities
Orange, California • Stanford, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Sep 11, 2026, 2:03 AM EDT
Completed Not applicable Interventional

Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel

NCT01821833
View directory record Official record
Conditions
Breast Cancer, Ovarian Neoplasm, Pain
Interventions
Omega-3 fatty acid, Placebo, Paclitaxel
Dietary Supplement · Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Sep 11, 2026, 2:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Intravenous Alcohol Administration Using BrAc Method in Healthy Subjects With and Without a Family History of Alcoholism

NCT00612352
View directory record Official record
Conditions
Alcoholism
Interventions
Ethanol High Dose, Ethanol Low Dose, and Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 30 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2015
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Sep 11, 2026, 2:03 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Chronic Kidney Disease (CKD) Platelet Study

NCT03649711
View directory record Official record
Conditions
Chronic Kidney Diseases, Heart Attack, Stroke, Ischemic
Interventions
Ticagrelor 90mg, Clopidogrel 75mg, Aspirin 81 mg
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 91 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
2
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Sep 11, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Results available

A Study of Cytisinicline for Vaping Cessation in Adult Smokers

NCT05431387
View directory record Official record
Conditions
Vaping, E-Cig Use
Interventions
cytisinicline, Placebo, Behavioral support
Drug · Behavioral
Lead sponsor
Achieve Life Sciences
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Lexington, Kentucky • Boston, Massachusetts • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 11, 2026, 2:03 AM EDT